J0872 — Injection, daptomycin (xellia), unrefrigerated, not therapeutically equivalent to j0878 or j0873, 1 mg
2,484,205 observed fee-for-service (44%) · ~3,183,435 estimated Medicare Advantage. Scaled from the observed floor by each state’s fee-for-service share (FFS share as of 2024) — scaled estimate — assumes MA utilization mirrors FFS; not an observation. How we scale
Disclosed Medicare fee-for-service services by billing state; open a bar for that state's ranked market. Average submitted charge / service by billing state, among the highest-volume states; open a bar for that state's ranked market.
- Market position — where this market sits on volume and growth among all state markets, and its rank.
- Worth a look — every state market for this search, ranked by a published score: size, growth, fragmentation, below-expected volume.
- Lookalike opportunities — groups billing below what peers of the same specialty, size, and state predict, with the expected figure shown.
- National benchmarks — where each group's volume sits nationally and within its specialty.
- Market structure — how concentrated this market is, and who owns the volume.
- Medicare-wide scaling — the exact payer split, and this market total scaled to all of Medicare, labeled as an estimate.
Nevvi's market analytics platform — code baskets, market structure and share, the twelve-year trend layer — is built and not launched yet. We're gathering interest in it.
Notify me at launch →Specialty market — Infectious Disease: 664,012 services — specialty benchmark suppressed (fewer than 11 groups) — showing state benchmark. See Infectious Disease across all states →
| # | Physician group | City | St | Specialty | Providers | J0872 svcs | Submitted charges | Avg charge | Medicare $ locked column | Share of specialty* | Share of state* | Phone |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | HOUSTON CENTER FOR INFECTIOUS DISEASES PA | THE WOODLANDS | TX | INFECTIOUS DISEASE | 9 | 427,881 | $351,015 | $1 | premium | — | 100.0% | (281) 444-1303 |
| 2 | DONNA M O'NEILL M.D. P.C. | JACKSON | MI | INFECTIOUS DISEASE | 2 | 100,750 | $100,750 | $1 | premium | — | 35.5% | (517) 788-4781 |
| 3 | GULF COAST INFECTIOUS DISEASES INC | PENSACOLA | FL | INFECTIOUS DISEASE | 4 | 54,501 | $54,501 | $1 | premium | — | 3.0% | (850) 549-4755 |
| 4 | ESSEX COUNTY INFECTIOUS DISEASE | BLOOMFIELD | NJ | INFECTIOUS DISEASE | 3 | 41,900 | $31,075 | $1 | premium | — | 100.0% | (973) 748-4583 |
| 5 | INFECTIOUS DISEASE ASSOCIATES PA | BOCA RATON | FL | INFECTIOUS DISEASE | 7 | 38,980 | $38,980 | $1 | premium | — | 2.2% | (561) 393-8224 |
*"Share of specialty" is the group's share of disclosed Medicare-FFS services for the primary code among groups with the SAME modal specialty in the state; "share of state" is the same figure against the whole state. Specialty is each group's modal member specialty from CMS's clinician register — a multi-specialty group carries one label. Where fewer than 11 groups share the specialty in the state, the specialty share renders "—" — the specialty benchmark is suppressed (fewer than 11 groups) and the state share alongside is the benchmark. Group figures sum clinicians affiliated with exactly one group. See Methods.
Comparing against an all-payer estimate?
These are exact counts from Medicare fee-for-service claims — roughly a third to half of most procedure markets, depending on payer mix. Modeled all-payer databases project the remainder statistically; we publish the audited floor and label it as such. Same market, different denominator. How the numbers reconcile →